Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept
NCT02353780 · Dr. Larry W. Moreland · PHASE4 · terminated · last registry update 2020-10-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low enrollment” | – | Registry record, Dr. Larry W. Moreland |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNF within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-10-01Also stopped (terminated): Schneider Children's Medical Center, Israel, Infliximab (NCT03209232)
- 2021-09-16Phase 3 first posted: Bio-Thera Solutions, BAT2506 + EU Simponi (NCT05046431)
- 2021-08-13Results posted on the registry: Hoffmann-La Roche, Etrolizumab + Infliximab (NCT02136069)
- 2021-08-10Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Fecal Microbiota Transplantation (FMT) + Sham-transplantation (placebo) (NCT04997733)
- 2021-07-28Results posted on the registry: University Health Network, Toronto, Infliximab (NCT02363738)
- 2021-07-23Phase 3 first posted: Children's Hospital Medical Center, Cincinnati, Infliximab precision dosing (NCT04974099)
- 2021-07-19Results posted on the registry: AbbVie, ABBV-3373 + Placebo for ABBV-3373 (NCT03823391)
- 2021-07-01Results posted on the registry: Guy's and St Thomas' NHS Foundation Trust, Golimumab (NCT03124121)
- 2021-06-23Also stopped (withdrawn): UCB Biopharma SRL, Certolizumab pegol + Adalimumab (NCT04643483)
- 2021-05-24Phase 3 first posted: University of California, San Diego, Infliximab + Anakinra (NCT04898231)
- 2021-03-12Also stopped (withdrawn): Children's Hospital of Fudan University, IVIG + Aspirin (NCT04535518)
- 2021-03-04Results posted on the registry: Janssen Scientific Affairs, LLC, Infliximab + Golimumab (NCT01804166)
- 2020-12-31Results posted on the registry: UCB Biopharma SRL, Certolizumab Pegol (NCT03020992)
- 2020-12-01Also stopped (terminated): Medical University of Graz, bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept) (NCT01602302)
- 2020-11-27Results posted on the registry: Columbia University, TNF inhibitors + DMARDs (NCT01548768)
- 2020-11-25Phase 3 first posted: UCB Biopharma SRL, Certolizumab pegol + Adalimumab (NCT04643483)
- 2020-11-18Results posted on the registry: Janssen Research & Development, LLC, Golimumab + Methotrexate (NCT02277444)
- 2020-11-06Results posted on the registry: Genentech, Inc., Infliximab + Methotrexate (NCT00808210)
- 2020-11-06Also stopped (terminated): Genentech, Inc., Infliximab + Methotrexate (NCT00808210)
- 2020-10-30Phase 3 first posted: University of Erlangen-Nürnberg Medical School, Prednisolone + Sulfasalazine (NCT04610476)
- 2020-10-20Phase 3 first posted: Daniel Benjamin, Infliximab + Abatacept (NCT04593940)
- 2020-10-05Results posted on the registry: Instituto de Medicina Molecular João Lobo Antunes, Golimumab + Methotrexate (NCT02065713)
- 2020-09-04Also stopped (terminated): IRCCS Burlo Garofolo, Thalidomide + Infliximab (NCT03221166)
- 2020-09-02Phase 3 first posted: Children's Hospital of Fudan University, IVIG + Aspirin (NCT04535518)
- 2020-08-17Results posted on the registry: UCB BIOSCIENCES GmbH, Certolizumab Pegol (NCT02552212)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision